Busch C, et al. - Researchers assessed the functional long-term outcome in patients with macular oedema (MO) secondary to central retinal vein occlusion (CRVO) and branch retinal vein occlusion (BRVO) treated with dexamethasone implant (DEX implant). They also identified its clinical predictors. As per data, for long-term outcome and the need of adjunctive intravitreal therapy in MO secondary to BRVO/CRVO treated by DEX implant the possible predictors were clinical baseline characteristics and the early treatment response.